Hansa Biopharma AB (publ) (LON:0RC7)
London · Delayed Price · Currency is GBP · Price in SEK 40.00
+3.64 (10.01%)
At close: Feb 11, 2026
Hansa Biopharma AB Market Cap
Hansa Biopharma AB has a market cap or net worth of 342.68 million as of February 12, 2026. Its market cap has increased by 115.68% in one year.
Market Cap
342.68M
Enterprise Value
361.81M
Revenue
17.92M
Ranking
n/a
PE Ratio
n/a
Stock Price
40.00
Market Cap Chart
Since April 24, 2008, Hansa Biopharma AB's market cap has increased from 2.62M to 342.68M, an increase of 12,990.21%. That is a compound annual growth rate of 31.47%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 12, 2026 | 342.68M | 21.36% |
| Dec 30, 2025 | 282.37M | 46.81% |
| Dec 30, 2024 | 192.34M | 79.82% |
| Dec 29, 2023 | 106.96M | -47.96% |
| Dec 30, 2022 | 205.52M | -36.47% |
| Dec 30, 2021 | 323.48M | -66.29% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Genus | 2.04B |
| Oxford Nanopore Technologies | 1.36B |
| Oxford Biomedica | 1.00B |
| PureTech Health | 305.01M |
| Avacta Group | 269.00M |
| Faron Pharmaceuticals Oy | 191.04M |
| Scancell Holdings | 133.61M |
| Bioventix | 90.13M |